Retifanlimab Demonstrated Antitumor Activity in MSI-H/dMMR Endometrial Cancer
The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Pseudoprogression With Immunotherapy in Cervical Cancer
A study evaluated characteristics of pseudoprogression among patients with cervical cancer treated with ICIs.
Clinical Trial: Combination of Letrozole Plus Abemaciclib in Estrogen Receptor–Positive Endometrial Cancer
Does abemaciclib and letrozole effective slow or stop endometrial cancer cell growth?
Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial Cancer
All patients will receive mirvetuximab soravtansine and pembrolizumab in this study.
Trial to Evaluate PORTEC-4a: Molecular Profile-Based vs Standard Adjuvant Radiotherapy in Endometrial Cancer
A phase 3 study seeks to evaluate the value of selecting therapy based on molecular profiling.
Clinical Trial: Phase 3 AtTEnd Trial in Endometrial Cancer
Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.
Use of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Has Doubled
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic Intraperitoneal Chemotherapy May Improve Outcomes in Epithelial Ovarian Cancer
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
Palbociclib Plus Letrozole Deemed Effective in Advanced Endometrial Cancer
Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
American Cancer Society Updates Cervical Cancer Screening Guidelines
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Clinically Significant Fatigue Common After Surgery for Gynecologic Cancers, Remains High 1 Year Later
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
PARP Inhibitors Deemed Too Costly for Across-the-Board Frontline Maintenance in Ovarian Cancer
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
ACS Issues Updated Guideline for Cervical Cancer Screening
Screening, preferably with primary HPV testing, should start at age 25 and continue through age 65.
Longitudinal MicroRNAs Lacked Predictive Value in Ovarian Cancer
Study results differ from prior research into microRNAs as predictive biomarkers.
Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer
This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.
Radiotherapy for Cervical Cancer: An Introduction to ASTRO’s Clinical Practice Guideline
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
Pap Tests May Hold Biomarkers Ahead of Ovarian Cancer Diagnosis
A proof-of-principle study confirms presence of TP53 variants ahead of diagnosis.
WEE1 Kinase Inhibitor Improved PFS in TP53-Mutated Ovarian Cancer
Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
